

SECURITIES AND EXCHANGE COMMISSION

FORM SC 13G/A

Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions [amend]

Filing Date: **2024-02-14**
SEC Accession No. [0001104659-24-023975](#)

[\(HTML Version on secdatabase.com\)](#)

SUBJECT COMPANY

Cullinan Oncology, Inc.

CIK:[1789972](#) | IRS No.: [813867811](#) | Fiscal Year End: [1231](#)
Type: **SC 13G/A** | Act: [34](#) | File No.: [005-91966](#) | Film No.: [24640076](#)
SIC: [2836](#) Biological products, (no diagnostic substances)

Mailing Address
*ONE MAIN STREET
SUITE 1350
CAMBRIDGE MA 02142*

Business Address
*ONE MAIN STREET
SUITE 1350
CAMBRIDGE MA 02142
617-410-4650*

FILED BY

Jovan-Embiricos Morana

CIK:[1575745](#)
Type: **SC 13G/A**

Mailing Address
*C/O RADIUS HEALTH, INC.
201 BROADWAY, 6TH FLOOR
BOSTON MA 02139*

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 2)

CULLINAN ONCOLOGY, INC.

(Name of Issuer)

Common Stock, \$0.0001 par value
(Title of Class of Securities)

230031106
(CUSIP Number)

December 31, 2023
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 230031106

1	NAME OF REPORTING PERSON Globeways Holdings Ltd.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>

3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 468,696 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 468,696 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 468,696 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.10% ⁽³⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN	

⁽¹⁾ Includes (i) 66,390 shares of Common Stock held by F2 Bioscience I 2017 Ltd. and (ii) 402,306 shares of Common Stock held by F2 MG Ltd. Globeways Holdings Ltd. is the appointed manager of and has sole power to vote upon the acquisition, holding and disposal of all shares held by each of F2 Bioscience I 2017 Ltd. and F2 MG Ltd.

⁽²⁾ Percentage based on 42,780,644 shares of Common Stock outstanding as of October 31, 2023, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.

CUSIP No. 230031106

1	NAME OF REPORTING PERSON F2 Bioscience I 2017 Ltd.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 66,390 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 66,390 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 66,390 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.16% ⁽²⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN	

⁽¹⁾ The reported securities are owned directly by F2 Bioscience I 2017 Ltd. Globeways Holdings Ltd. is the appointed manager of F2 Bioscience I 2017 Ltd. and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience I 2017 Ltd.

⁽²⁾ Percentage based on 42,780,644 shares of Common Stock outstanding as of October 31, 2023, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.

CUSIP No. 230031106

1	NAME OF REPORTING PERSON F2 MG Ltd.	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER

REPORTING PERSON WITH		402,306 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 402,306 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 402,306 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.94% ⁽²⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN	

⁽¹⁾ The reported securities are owned directly by F2 MG Ltd. Globeways Holdings Ltd. is the appointed manager of F2 MG Ltd. and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Ltd.

⁽²⁾ Percentage based on 42,780,644 shares of Common Stock outstanding as of October 31, 2023, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.

CUSIP No. 230031106

1	NAME OF REPORTING PERSON Globeways Holdings II Ltd.	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 1,013,334 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER

	1,013,334 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,013,334 ⁽¹⁾
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.37% ⁽²⁾
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN

⁽¹⁾ Includes (i) 622,175 shares of Common Stock held by F2-TPO Investments, LLC, (ii) 71,599 shares of Common Stock held by F2 Bio TD, LLC, (iii) 214,798 shares of Common Stock held by F2 MC, LLC, and (iv) 104,762 shares of Common Stock held by F2 GC, LLC. Globeways Holdings II Ltd. is the appointed manager of and has sole power to vote upon the acquisition, holding and disposal of all shares held by each of F2-TPO Investments, LLC, F2 Bio TD, LLC, F2 MC, LLC and F2 GC, LLC.

⁽²⁾ Percentage based on 42,780,644 shares of Common Stock outstanding as of October 31, 2023, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.

CUSIP No. 230031106

1	NAME OF REPORTING PERSON F2-TPO Investments, LLC	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 622,175 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 622,175 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 622,175 ⁽¹⁾	

10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.45% ⁽²⁾
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

(1) The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Ltd. is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC.

(2) Percentage based on 42,780,644 shares of Common Stock outstanding as of October 31, 2023, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.

CUSIP No. 230031106

1	NAME OF REPORTING PERSON F2 Bio TD, LLC	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 71,599 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 71,599 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 71,599 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	

	0.17% ⁽²⁾
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

⁽¹⁾ The reported securities are owned directly by F2 Bio TD, LLC. Globeways Holdings Ltd. is the appointed manager of F2 Bio TD, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio TD, LLC.

⁽²⁾ Percentage based on 42,780,644 shares of Common Stock outstanding as of October 31, 2023, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.

CUSIP No. 230031106

1	NAME OF REPORTING PERSON F2 MC, LLC	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 214,798 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 214,798 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 214,798 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.50% ⁽²⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO	

(1) The reported securities are owned directly by F2 MC, LLC. Globeways Holdings II Ltd. is the appointed manager of F2 MC, LLC. and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC, LLC.

(2) Percentage based on 42,780,644 shares of Common Stock outstanding as of October 31, 2023, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.

CUSIP No. 230031106

1	NAME OF REPORTING PERSON F2 GC, LLC	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 104,762 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 104,762 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 104,762 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.24% ⁽²⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO	

(1) The reported securities are owned directly by F2 GC, LLC. Globeways Holdings II Ltd. is the appointed manager of F2 GC, LLC. and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC, LLC.

(2) Percentage based on 42,780,644 shares of Common Stock outstanding as of October 31, 2023, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.

CUSIP No. 230031106

1	NAME OF REPORTING PERSON F2 Vision Management Sarl	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Luxembourg	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 0 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 0 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0% ⁽²⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO	

⁽¹⁾ The reported securities are owned directly by F2 Vision SCS. F2 Vision Management Sarl is the appointed manager of and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision SCS.

⁽²⁾ Percentage based on 42,780,644 shares of Common Stock outstanding as of October 31, 2023, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.

CUSIP No. 230031106

1	NAME OF REPORTING PERSON F2 Vision SCS	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION Luxembourg	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 0 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 0 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0% ⁽²⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN	

⁽¹⁾ The reported securities are owned directly by F2 Vision SCS. F2 Vision Management Sarl is the appointed manager of and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision SCS.

⁽²⁾ Percentage based on 42,780,644 shares of Common Stock outstanding as of October 31, 2023, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.

CUSIP No. 230031106

1	NAME OF REPORTING PERSON Wolfways Holdings Limited	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	

3	SEC USE ONLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 0
	6	SHARED VOTING POWER 487,628 ⁽¹⁾
	7	SOLE DISPOSITIVE POWER 0
	8	SHARED DISPOSITIVE POWER 487,628 ⁽¹⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 487,628 ⁽¹⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.14% ⁽²⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN	

⁽¹⁾ The reported securities are owned directly by Wolfways Holdings Limited.

⁽²⁾ Percentage based on 42,780,644 shares of Common Stock outstanding as of October 31, 2023, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.

CUSIP No. 230031106

1	NAME OF REPORTING PERSON Morana Jovan-Embiricos
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION United Kingdom

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 207,803 ⁽¹⁾
	6	SHARED VOTING POWER 1,969,658 ⁽²⁾⁽³⁾⁽⁴⁾
	7	SOLE DISPOSITIVE POWER 207,803 ⁽¹⁾
	8	SHARED DISPOSITIVE POWER 1,969,658 ⁽²⁾⁽³⁾⁽⁴⁾
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,177,461 ⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾	
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) <input type="checkbox"/>	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.09% ⁽⁵⁾	
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN	

⁽¹⁾ Includes 207,803 shares of Common Stock directly held by Dr. Morana Jovan-Embiricos.

⁽²⁾ Includes (i) 66,390 shares of Common Stock held by F2 Bioscience I 2017 Ltd. and (ii) 402,306 shares of Common Stock held by F2 MG Ltd. Globeways Holdings Ltd. is the appointed manager of and has sole power to vote upon the acquisition, holding and disposal of all shares held by each of F2 Bioscience I 2017 Ltd. and F2 MG Ltd. Dr. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Ltd. and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways Holdings Ltd.

⁽³⁾ Includes (i) 622,175 shares of Common Stock held by F2-TPO Investments, LLC, (ii) 71,599 shares of Common Stock held by F2 Bio TD, LLC, (iii) 214,798 shares of Common Stock held by F2 MC, LLC, and (iv) 104,762 shares of Common Stock held by F2 GC, LLC. Globeways Holdings II Ltd. is the appointed manager of and has sole power to vote upon the acquisition, holding and disposal of all shares held by each of F2-TPO Investments, LLC, F2 Bio TD, LLC, F2 MC, LLC and F2 GC, LLC. Dr. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Ltd. and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways Holdings II Ltd.

⁽⁴⁾ Includes 487,628 shares of Common Stock held by Wolfways Holdings Limited. Dr. Morana Jovan-Embiricos is the founding director of Wolfways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Wolfways Holdings Limited.

⁽⁵⁾ Percentage based on 42,780,644 shares of Common Stock outstanding as of October 31, 2023, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.

Item 1.

(a) Name of Issuer

Cullinan Oncology, Inc.

(b) Address of Issuer's Principal Executive Offices

One Main Street, Suite 1350
Cambridge, MA 02142

Item 2.

(a) Names of Persons Filing

Globeways Holdings Ltd.
F2 Bioscience I 2017 Ltd.
F2 MG Ltd.
Globeways Holdings II Ltd.
F2-TPO Investments, LLC
F2 Bio TD, LLC
F2 MC, LLC
F2 GC, LLC
F2 Vision Management Sarl
F2 Vision SCS
Wolfways Holdings Limited
Morana Jovan-Embiricos

(b) Address of Principal Business office or, if None, Residence

Globeways Holdings Ltd.
c/o LJ Management (Suisse) SA
7 Rue de la Confederation
Geneva 1204
Switzerland

F2 Bioscience I 2017 Ltd.
c/o LJ Management (Suisse) SA
7 Rue de la Confederation
Geneva 1204
Switzerland

F2 MG Ltd.
c/o GISEV (Suisse) SA
Contrada di Sassello 2
6900 Lugano
Switzerland

Globeways Holdings II Ltd.
c/o LJ Management (Suisse) SA
7 Rue de la Confederation
Geneva 1204
Switzerland

F2-TPO Investments, LLC
c/o Twin Focus
75 Park Plaza
Boston
Massachusetts 02116
USA

F2 Bio TD, LLC
c/o Twin Focus
75 Park Plaza
Boston
Massachusetts 02116
USA

F2 MC, LLC
c/o Twin Focus
75 Park Plaza
Boston
Massachusetts 02116
USA

F2 GC, LLC
c/o Twin Focus
75 Park Plaza
Boston
Massachusetts 02116
USA

F2 Vision Management Sarl
c/o Atalux
74 Grand-Rue
Luxembourg V8 L-1660

F2 Vision SCS
c/o Atalux
74 Grand-Rue
Luxembourg V8 L-1660

Wolfways Holdings Limited
c/o LJ Management (Suisse) SA
7 Rue de la Confederation
Geneva 1204
Switzerland

Morana Jovan-Embiricos
c/o LJ Management (Suisse) SA
7 Rue de la Confederation
Geneva 1204
Switzerland

(c) Citizenship

Globeways Holdings Ltd.	British Virgin Islands
F2 Bioscience I 2017 Ltd.	British Virgin Islands
F2 MG Ltd.	British Virgin Islands
Globeways Holdings II Ltd.	British Virgin Islands

F2-TPO Investments, LLC	Delaware
F2 Bio TD, LLC	Delaware
F2 MC, LLC	Delaware
F2 GC, LLC	Delaware
F2 Vision Management Sarl	Luxembourg
F2 Vision SCS	Luxembourg
Wolfways Holdings Limited	British Virgin Islands
Morana Jovan-Embircos	United Kingdom

- (d) Title of Class of Securities
Common Stock, par value \$0.0001 per share
- (e) CUSIP Number
230031106

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
- (k) Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4. Ownership.

(a) and (b) Amount beneficially owned:

- (i) F2 Bioscience I 2017 Ltd. directly owns 66,390 shares of Common Stock, which represents approximately 0.16% of the outstanding shares of Common Stock.
- (ii) F2 MG Ltd. directly owns 402,306 shares of Common Stock, which represents approximately 0.94% of the outstanding shares of Common Stock.
- (iii) F2-TPO Investments, LLC directly owns 622,175 shares of Common Stock, which represents approximately 1.45% of the outstanding shares of Common Stock.
- (iv) F2 Bio TD, LLC directly owns 71,599 shares of Common Stock, which represents approximately 0.17% of the outstanding Common Stock.
- (v) F2 MC, LLC directly owns 214,798 shares of Common Stock, which represents approximately 0.50% of the outstanding shares of Common Stock.
- (vi) F2 GC, LLC directly owns 104,762 shares of Common Stock, which represents approximately 0.24% of the outstanding shares of Common Stock.
- (vii) F2 Vision SCS no longer owns shares of Common Stock.
- (viii) Wolfways Holdings Limited directly owns 487,628 shares of Common Stock, which represents approximately 1.14% of the outstanding shares of Common Stock.

(ix) Globeways Holdings Ltd. is the appointed manager of and has sole power to vote upon the acquisition, holding and disposal of all shares of Common Stock held by F2 Bioscience I 2017 Ltd. and F2 MG Ltd. In addition, Thus, Globeways Holdings Ltd. may be deemed to beneficially own 468,696 shares of Common Stock, which represents approximately 1.10% of the outstanding shares of Common Stock.

(x) Globeways Holdings II Ltd. is the appointed manager of and has sole power to vote upon the acquisition, holding and disposal of all shares of Common Stock held by F2-TPO Investments, LLC, F2 Bio TD, LLC, F2 MC, LLC and F2 GC, LLC. Thus, Globeways Holdings II Ltd. may be deemed to beneficially own 1,013,334 shares of Common Stock, which represents approximately 2.37% of the outstanding shares of Common Stock.

(xi) F2 Vision Management Sarl is the appointed manager of and has sole power to vote upon the acquisition, holding and disposal of all shares of Common Stock held by F2 Vision SCS. F2 Vision SCS no longer owns shares of Common Stock and, thus, F2 Vision Management Sarl does not beneficially own shares of Common Stock.

(xii) Dr. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Ltd., Globeways Holdings II Ltd. and Wolfways Holdings Limited, and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways Holdings Ltd., Globeways Holdings II Ltd. and Wolfways Holdings Limited. In addition, Dr. Jovan-Embiricos directly holds 207,803 shares of Common Stock. Thus, Dr. Jovan-Embiricos may be deemed to beneficially own 2,177,461 shares of Common Stock, which represents approximately 5.09% of the outstanding shares of Common Stock.

(c) Number of shares as to which such person has:

Reporting Person	Number of Shares of Common Stock			
	(i)	(ii)	(iii)	(iv)
F2 Bioscience I 2017 Ltd.	0	66,390	0	66,390
F2 MG Ltd.	0	402,306	0	402,306
F2-TPO Investments, LLC	0	622,175	0	622,175
F2 Bio TD, LLC	0	71,599	0	71,599

F2 MC, LLC	0	214,798	0	214,798
F2 GC, LLC	0	104,762	0	104,762
F2 Vision SCS	0	0	0	0
Wolfways Holdings Limited	0	487,628	0	487,628
Globeways Holdings Ltd.	0	468,696	0	468,696
Globeways Holdings II Ltd.	0	1,013,334	0	1,013,334
F2 Vision Management Sarl	0	0	0	0
Morana Jovan-Embiricos	207,803	1,969,658	207,803	1,969,658

- (i) Sole power to vote or direct the vote
- (ii) Shared power to vote or to direct the vote
- (iii) Sole power to dispose or to direct the disposition of
- (iv) Shared power to dispose or to direct the disposition of

Percentage based on 42,780,644 shares of Common Stock outstanding as of October 31, 2023, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

N/A

Item 8. Identification and Classification of Members of the Group.

N/A

Item 9. Notice of Dissolution of Group.

N/A

Item 10. Certifications.

N/A

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2024

GLOBEWAYS HOLDINGS LTD.

By: /s/ Morana Jovan-Embiricos

Name: Morana Jovan-Embiricos

Title: Director

F2 BIOSCIENCE I 2017 LTD.

By: /s/ Rachel Higham and Robert Burton

Names: Rachel Higham and Robert Burton

Titles: Directors

F2 MG LTD.

By: /s/ Achille Gregory Severgnini

Names: Achille Gregory Severgnini

Titles: Director

GLOBEWAYS HOLDINGS II LTD.

By: /s/ Morana Jovan-Embiricos

Name: Morana Jovan-Embiricos

Title: Director

F2-TPO INVESTMENTS LLC

By: /s/ Morana Jovan-Embiricos

Name: Morana Jovan-Embiricos

Title: Director

F2 BIO TD, LLC

By: /s/ Morana Jovan-Embiricos

Name: Morana Jovan-Embiricos

Title: Director

F2 MC, LLC

By: /s/ Morana Jovan-Embiricos

Name: Morana Jovan-Embiricos

Title: Director

F2 GC, LLC

By: /s/ Morana Jovan-Embiricos

Name: Morana Jovan-Embiricos

Title: Director

F2 VISION MANAGEMENT SARL

By: /s/ Alain Renard and Christian Francois

Name: Alain Renard and Christian Francois
Title: Directors

F2 VISION SCS

By: /s/ Alain Renard and Christian Francois
Name: Alain Renard and Christian Francois
Title: Directors

WOLFWAYS HOLDINGS LIMITED

By: /s/ Morana Jovan-Embiricos
Names: Morana Jovan-Embiricos
Titles: Director

/s/ Morana Jovan-Embiricos
Morana Jovan-Embiricos

JOINT FILING AGREEMENT

Each of the undersigned, pursuant to Rule 13d-1(k)(1) under the Act, hereby agrees and acknowledges that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the Common Stock and the information required by this Schedule 13G, to which this Agreement is attached as an exhibit, is filed on behalf of them. The undersigned further agree that any further amendments or supplements thereto shall also be filed on behalf of each of them.

GLOBEWAYS HOLDINGS LTD.By: /s/ Morana Jovan-Embiricos

Name: Morana Jovan-Embiricos

Title: Director

F2 BIOSCIENCE I 2017 LTD.By: /s/ Rachel Higham and Robert Burton

Names: Rachel Higham and Robert Burton

Titles: Directors

F2 MG LTD.By: /s/ Achille Gregory Severgnini

Names: Achille Gregory Severgnini

Titles: Director

GLOBEWAYS HOLDINGS II LTD.By: /s/ Morana Jovan-Embiricos

Name: Morana Jovan-Embiricos

Title: Director

F2-TPO INVESTMENTS LLCBy: /s/ Morana Jovan-Embiricos

Name: Morana Jovan-Embiricos

Title: Director

F2 BIO TD, LLCBy: /s/ Morana Jovan-Embiricos

Name: Morana Jovan-Embiricos

Title: Director

F2 MC, LLCBy: /s/ Morana Jovan-Embiricos

Name: Morana Jovan-Embiricos

Title: Director

F2 GC, LLCBy: /s/ Morana Jovan-Embiricos

Name: Morana Jovan-Embiricos

Title: Director

F2 VISION MANAGEMENT SARL

By: /s/ Alain Renard and Christian Francois _____

Name: Alain Renard and Christian Francois

Title: Directors

F2 VISION SCS

By: /s/ Alain Renard and Christian Francois _____

Name: Alain Renard and Christian Francois

Title: Directors

WOLFWAYS HOLDINGS LIMITED

By: /s/ Morana Jovan-Embiricos _____

Names: Morana Jovan-Embiricos

Titles: Director

/s/ Morana Jovan-Embiricos _____

Morana Jovan-Embiricos
